ScholarLens Back to search
2014•Breast Cancer Research and TreatmentOpen access

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Vakaramoko Diaby, Georges Adunlin, Simon Blechman Zeichner, Kiran Kumar Venkata Raja Avancha, Gilberto De Lima Lopes Jr., Stefan Glück, Alberto J. Montero

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Exemestane, Everolimus, Medicine, Oncology, Breast cancer, Hormone receptor, Metastatic breast cancer, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer — Research Paper | ScholarLens